Association of the British Pharmaceutical Industry Criticises NICE’s Proposed Appraisals Modifications
NHS England and the National Institute for Health and Care Excellence are planning a series of modifications to the way in which technologies are appraised, for example, one of the proposals is to automatically fund, from routine commissioning budgets, treatments for very rare conditions up to £100,000 per QALY.
The Association of the British Pharmaceutical Industry has described new proposals for evaluating medicines for NHS use as “heavy handed” and “unrealistic”.
